Forte Biosciences Inc
NASDAQ:FBRX
Forte Biosciences Inc
NASDAQ:FBRX
Price:
28.81
USD
-10.08%
Market Closed
Market Cap:
$361m
Balance Sheet
Balance Sheet Decomposition
Forte Biosciences Inc
Forte Biosciences Inc
Balance Sheet Decomposition is not available for
Forte Biosciences Inc
Forte Biosciences Inc
Balance Sheet
Forte Biosciences Inc
Forte Biosciences Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
3
|
4
|
8
|
6
|
36
|
41
|
9
|
59
|
42
|
41
|
37
|
22
|
|
| Cash Equivalents |
3
|
4
|
8
|
6
|
36
|
41
|
9
|
59
|
42
|
41
|
37
|
22
|
|
| Short-Term Investments |
31
|
26
|
51
|
26
|
53
|
55
|
13
|
0
|
0
|
0
|
0
|
36
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
2
|
2
|
1
|
1
|
1
|
0
|
1
|
3
|
|
| Total Current Assets |
35
|
31
|
60
|
33
|
91
|
98
|
23
|
60
|
43
|
42
|
38
|
61
|
|
| PP&E Net |
1
|
1
|
0
|
1
|
1
|
4
|
5
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
1
|
1
|
0
|
1
|
1
|
4
|
5
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
2
|
2
|
2
|
2
|
3
|
3
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
2
|
2
|
0
|
1
|
0
|
1
|
1
|
1
|
0
|
0
|
|
| Total Assets |
36
N/A
|
31
-13%
|
62
+101%
|
35
-43%
|
92
+160%
|
103
+12%
|
28
-73%
|
61
+117%
|
43
-29%
|
42
-3%
|
39
-7%
|
62
+58%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
1
|
1
|
1
|
2
|
2
|
3
|
3
|
1
|
1
|
1
|
1
|
5
|
|
| Accrued Liabilities |
1
|
2
|
4
|
5
|
8
|
13
|
5
|
1
|
1
|
2
|
2
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
1
|
7
|
7
|
0
|
5
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
2
|
3
|
6
|
14
|
17
|
17
|
13
|
2
|
2
|
3
|
4
|
9
|
|
| Long-Term Debt |
0
|
0
|
17
|
14
|
4
|
26
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
2
|
4
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
2
N/A
|
4
+46%
|
23
+560%
|
28
+23%
|
21
-26%
|
45
+114%
|
17
-61%
|
2
-87%
|
2
-22%
|
3
+78%
|
4
+15%
|
9
+148%
|
|
| Equity | |||||||||||||
| Common Stock |
89
|
98
|
131
|
131
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
57
|
72
|
95
|
128
|
167
|
216
|
279
|
52
|
73
|
87
|
119
|
154
|
|
| Additional Paid In Capital |
1
|
1
|
2
|
4
|
238
|
274
|
290
|
110
|
115
|
126
|
154
|
206
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
33
N/A
|
28
-17%
|
39
+42%
|
7
-82%
|
71
+916%
|
58
-18%
|
11
-81%
|
59
+446%
|
42
-30%
|
39
-7%
|
35
-9%
|
52
+49%
|
|
| Total Liabilities & Equity |
36
N/A
|
31
-13%
|
62
+101%
|
35
-43%
|
92
+160%
|
103
+12%
|
28
-73%
|
61
+117%
|
43
-29%
|
42
-3%
|
39
-7%
|
62
+58%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
2
|
2
|
13
|
15
|
21
|
1
|
6
|
|
Switch to:
Switch to:
See Also
Discover More
